Drugs / Invivo CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07239323 | Jul 2025 → Dec 2027 expected | B-cell acute lymphoblastic leukemia, plasma cell myeloma | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Invivo CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07239323 ↗ |
| Modality | Cell therapy | “in vivo Chimeric Antigen Receptor T-Cell(CAR-T cell) therapy” NCT07239323 ↗ |
| Route | Intravenous | “receive an intravenous infusion of the in Vivo CAR-T preparation” NCT07239323 ↗ |
| Target | CD19 | “Chimeric Antigen Receptor T-cell Therapy Targeting CD19” NCT07239323 ↗ |